CGRP Forum is made possible thanks to support from AbbVie, Lilly, Organon and Pfizer, all of whom have no influence or control of editorial content. More information is available here »
Study title/design: Cluster headache treatment with rimegepant – Open Label Pilot Study (Phase 2, NCT05264714) Trial NCT05264714 Aim To explore the efficacy of rimegepant as a preventative therapy for cluster headache. Study design After establishing episodic and chronic cluster headache pattern in a one-week baseline including frequency, severity, and abortive medicine use, patients will be …
Read more »Study title/design: A Phase 4, randomized, double-blind, placebo-controlled study to evaluate the efficacy and tolerability of rimegepant for the prevention of migraine in adults with a history of inadequate response to oral preventive medications (NCT05518123) Trial NCT05518123 – recruiting Aim To evaluate the efficacy and tolerability of rimegepant for migraine prophylaxis in adults with a …
Read more »Study title/design: A Phase 4, randomized, double-blind placebo-controlled, efficacy and tolerability trial of rimegepant for the acute treatment of migraine in adults unsuitable for triptan use (NCT05509400) Trial NCT05509400 Aim To evaluate the efficacy and tolerability of rimegepant in adult patients unsuitable for triptan medications due to a previous intolerance, lack of efficacy, or contraindication …
Read more »Study title/design: A Phase 4, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of galcanezumab versus rimegepant in adult participants with episodic migraine (CHALLENGE-MIG, NCT05127486) Trial NCT05127486 Aim To assess whether galcanezumab is superior to rimegepant in the prevention of migraine in participants with episodic migraine. Study design Randomised, double-blind, placebo-controlled study evaluating the …
Read more »Study title/design: Long-term safety study of rimegepant for acute treatment of migraine in paediatric patients (NCT04743141) Trial NCT04743141 Aim To test the long-term safety and efficacy of rimegepant in the acute treatment of moderate or severe migraine in children and adolescents Study design Phase 3, multicentre, open-label study of rimegepant 50 mg or 75 mg …
Read more »Study title/design: Rimegepant for acute treatment of migraine in children and adolescents (NCT04649242) Trial NCT045649242 Aim To test the safety and efficacy of rimegepant in the acute treatment of moderate or severe migraine in children and adolescents Study design Phase 3, multicentre, randomised, double-blind, group sequential placebo-controlled study of rimegepant 50 mg or 75 mg …
Read more »Study title/design: An open-label, intermediate size, expanded access study of rimegepant in the acute treatment of migraine (NCT03934086) Trial NCT03934086 – No longer available Aim To allow patients who completed any other rimegepant clinical study to have access to rimegepant while collecting ongoing safety data. (No longer available) Study design Adults (> 18 years) treated …
Read more »Study title/design: A Phase 2/3, double-blind, placebo-controlled study to evaluate the efficacy and safety of rimegepant in migraine prevention (NCT03732638) Trial NCT03732638 Aim To evaluate the efficacy and safety of rimegepant in patients with migraine Study design Study of patients aged > 18 years randomised to rimegepant 75 mg tablet or placebo for 12 weeks …
Read more »Study title/design: A Phase 2 double-blind, placebo controlled crossover trial of rimegepant for treatment of refractory trigeminal neuralgia (NCT03941834) Trial NCT03941834 – Terminated Aim To evaluate the efficacy of rimegepant compared to placebo in patients with treatment refractory trigeminal neuralgia (TN). Study design Adults (> 18 years) randomised to rimegepant 75 mg tablet or placebo. …
Read more »Rimegepant (BVH-3000) Study title/design: Phase 3: double-blind, randomised, placebo-controlled, safety and efficacy trial of BHV-3000 (rimegepant) for the acute treatment of migraine (Study 301) Trial NCT03235479: https://clinicaltrials.gov/ct2/show/NCT03235479?term=rimegepant&draw=1&rank=5 Aim To compare the efficacy of BHV-3000 (rimegepant) versus placebo in patients with acute migraines Study design A total of 1162 patients were randomised to rimegepant 75 mg …
Read more »Rimegepant (BVH-3000) Study title/design: Phase 3: double-blind, randomised, placebo-controlled, safety and efficacy trial of BHV-3000 (rimegepant) for the acute treatment of migraine (Study 302) Trial NCT03237845: https://clinicaltrials.gov/ct2/show/NCT03237845?term=rimegepant&rank=1 Aim To compare the efficacy of BHV-3000 (rimegepant) versus placebo in patients with acute migraines Study design A total of 1186 patients were randomised to rimegepant 75 mg …
Read more »Rimegepant (BVH-3000) Study title/design: A multicentre, open label long-term safety study of BHV3000 in the acute treatment of migraine Trial NCT03266588: https://clinicaltrials.gov/ct2/show/NCT03266588?term=rimegepant&rank=3 Aim To evaluate the safety and tolerability of rimegepant 75 mg oral tablet Study design 1800 patients received rimegepant 75 mg: 1033 patients with 2-8 moderate to severe migraine attacks/month, dosing as needed …
Read more »Rimegepant (BVH-3000) Study title/design: Phase 3, double-blind, randomised, placebo controlled, safety and efficacy trial of BHV-3000 (rimegepant) orally disintegrating tablet (ODT) for the acute treatment of migraine Trial NCT03461757: https://clinicaltrials.gov/ct2/show/NCT03461757?term=rimegepant&rank=2 Aim To compare the efficacy of BHV-3000 (rimegepant ODT) versus placebo in patients with acute migraines Study design 1466 patients were randomised to rimegepant 75 …
Read more »
This program is funded in part via an independent educational grant from AbbVie.
Organon has provided sponsorship towards this independent resource. Organon has had no editorial input or control over content, nor opportunity to influence.
Financial support was provided as GMG Knowledge Gap Grant from Pfizer Inc, Pfizer have provided only financial support and had no input into the content provided.
